Table VII.
Interventional clinical trials of replacement therapies for non-coding RNAs.
| Therapeutic oligonucleotide | Cancer type | Therapeutic approach | ClinicalTrials.gov identifier |
|---|---|---|---|
| MRX34 | Primary liver cancer or other selected solid tumors and hematologic malignancies | Monotherapy with MRX34 to investigate the safety and tolerability of escalating doses | NCT01829971 |
| TargomiRs | Recurrent malignant pleural mesothelioma and non-small cell lung cancer | Single-drug TargomiR | NCT02369198 |
| DTA-H19 | Unresectable, locally advanced pancreatic cancer and advanced-stage ovarian cancer | Monotherapy intratumoral with DTA-H19 | NCT00826150 |
| Non-muscle invasive bladder cancer | Monotherapy BC-819 instilled intravesical into the bladder | NCT03719300 | |
| Superficial transitional cell bladder carcinoma and locally advanced pancreatic adenocarcinoma | BC-819 and bacillus Calmette-Guérin vaccine | NCT01878188 | |
| BC-819 | Advanced HCC | BC-819 and gemcitabine | NCT01413087 |
| (inodiftagene | |||
| vixteplasmid) | Lung, ovarian, pancreatic, gall bladder, HCC, neuroendocrine, and cholangiocarcinoma | Monotherapy or in combination with sorafenib | NCT02716012 |
| MTL-CEBPA | Solid tumor in adult population | MTL-CEBPA in combination with a PD-1 inhibitor pembrolizumab | NCT04105335 |
| Advanced HCC | MTL-CEBPA plus sorafenib or sorafenib alone | NCT04710641 | |
| Advanced HCC | MTL-CEBPA, atezolizumab and bevacizumab | NCT05097911 |
HCC, hepatocellular carcinoma; PD-1, programmed cell death protein 1; TargomiR, miRNA mimics based on the miR-15/16 consensus sequence; MTL-CEBPA, RNA duplex activating of the c/ebpa gen transcription; CEBPA, CCAAT/enhancer-binding protein α; MRX34, mimic of miR-34a; DTA, DNA plasmid that carries the gene for the diphtheria toxin A.